Combination of docetaxel and cetuximab for penile cancer: A case report and literature review

Pasquale Rescigno, Elide Matano, Lucia Raimondo, Ciro Mainolfi, Piera Federico, Carlo Buonerba, Rossella Di Trolio, Carmine D'Aniello, Vincenzo Damiano, Giovannella Palmieri, Sabino De Placido, Giuseppe Di Lorenzo

Research output: Contribution to journalArticlepeer-review


Guidelines on the treatment of metastatic squamous cell carcinoma of the penis are limited to a few prospective trials. Cisplatin-based regimens represent the standard of treatment with promising activity of taxanes. Recently, epidermal growth factor receptor overexpression has been shown in these patients. We treated an elderly man with a docetaxel-cetuximab combination after failure of the cisplatin regimen. We observed a necrosis of the inguinal lymph nodes and a reduction of F-fluorodeoxyglucose uptake at PET/CT scan. Only mild mucositis and skin toxicity had been detected. Our case report, the first in the literature, shows that this combination is active and well tolerated in penile squamous cell carcinoma.

Original languageEnglish
Pages (from-to)573-577
Number of pages5
JournalAnti-Cancer Drugs
Issue number5
Publication statusPublished - Jun 2012


  • cetuximab
  • chemotherapy
  • metastatic penile cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology


Dive into the research topics of 'Combination of docetaxel and cetuximab for penile cancer: A case report and literature review'. Together they form a unique fingerprint.

Cite this